Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Esophageal Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Mesothelioma, Malignant 1Mesothelioma 1Liver Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 13Gemcitabine 12Cyclophosphamide 10Carboplatin 10Specimen Handling 8Magnetic Resonance Spectroscopy 8Cisplatin 8Docetaxel 7X-Rays 6Filgrastim 6Doxorubicin 6Biopsy 6tislelizumab 5Radiosurgery 5Phantoms, Imaging 5Paclitaxel 5Nivolumab 5Irinotecan 5Bevacizumab 5130-nm albumin-bound paclitaxel 5spartalizumab 4palbociclib 4Thiotepa 4Temozolomide 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Mesna 4Ipilimumab 4Imatinib Mesylate 4Ifosfamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × alvocidib × Gastrointestinal × Clear all
NCT00098579 2013-03-19

Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Completed
36 enrolled
GastrointestinalSarcoma

Sarcoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡